U.S. preeclampsia laboratory testing market will rise at a healthy CAGR of 5.1% during the forecast period of 2021-2026, reaching a market volume of ~4,629,000 by 2026. As countries undergo an escalated rate of health-related risks, preeclampsia is reported as the third leading cause of maternal mortality in the U.S alone. The scope of reproductive care now widely encompasses preeclampsia...